z-logo
open-access-imgOpen Access
Sodium Caseinate in Combination With Daunorubicin or Cytarabine Improves Survival of Mice With Long-established Leukemia
Author(s) -
Itzen Aguíñiga-Sánchez,
Edgar LedesmaMartínez,
José Luis Lara-Castañeda,
Frida Montserrat Meléndez-Ibarra,
Benny WeissSteider,
Isabel SotoCruz,
Guadalupe R. Fajardo-Orduña,
Edelmiro SantiagoOsorio
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10133
Subject(s) - daunorubicin , cytarabine , leukemia , bone marrow , myeloid leukemia , medicine , immunology , pharmacology
Although acute myeloid leukemia (AML) has traditionally been considered an oncological emergency and initiation of therapy is believed to be crucial to minimizing disease-related morbidity and mortality, it has also been suggested that a certain delay in treatment has no negative consequences in terms of response, early mortality, or survival. We aimed to determine the effect of administration of sodium caseinate (SC), a salt of casein, the main milk protein, with cytarabine or with daunorubicin on survival in mice with well-established leukemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here